Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Iovance Biotherapeutics (IOVA) FCF Margin (2023 - 2025)

Historic FCF Margin for Iovance Biotherapeutics (IOVA) over the last 4 years, with Q3 2025 value amounting to 132.75%.

  • Iovance Biotherapeutics' FCF Margin fell 281300.0% to 132.75% in Q3 2025 from the same period last year, while for Sep 2025 it was 140.5%, marking a year-over-year increase of 2712200.0%. This contributed to the annual value of 221.9% for FY2024, which is 320834000.0% up from last year.
  • Per Iovance Biotherapeutics' latest filing, its FCF Margin stood at 132.75% for Q3 2025, which was down 281300.0% from 124.94% recorded in Q2 2025.
  • Over the past 5 years, Iovance Biotherapeutics' FCF Margin peaked at 104.62% during Q3 2024, and registered a low of 42587.82% during Q2 2023.
  • Over the past 3 years, Iovance Biotherapeutics' median FCF Margin value was 270.34% (recorded in 2025), while the average stood at 9812.54%.
  • In the last 5 years, Iovance Biotherapeutics' FCF Margin skyrocketed by 422699600bps in 2024 and then plummeted by -281300bps in 2025.
  • Iovance Biotherapeutics' FCF Margin (Quarter) stood at 18153.32% in 2023, then skyrocketed by 99bps to 105.15% in 2024, then dropped by -26bps to 132.75% in 2025.
  • Its FCF Margin was 132.75% in Q3 2025, compared to 124.94% in Q2 2025 and 222.83% in Q1 2025.